Movement Alert｜SPYRE THERAPEUTICS INC Rises 6.15% in Regular Trading, Biotech Sector Gains Broadly

Market Focus10-10

On October 10, SPYRE THERAPEUTICS INC rose 6.15% in regular trading, trading at $84.84 per share, with turnover of $32.35 million.

The gain came after the stock fell over 13% on October 7 following the pricing of a $350 million underwritten public offering, and reflects a rebound alongside strength across the biotechnology sector.

Within the biotechnology sector, Moderna rose 8.86%, Twist Bioscience Corp gained 6.05%, Gilead Sciences added 2.34%, AbbVie advanced 1.46%, and Amgen increased 1.37%.

SPYRE THERAPEUTICS INC is a clinical-stage biotechnology company developing next-generation inflammatory bowel disease therapies, with a pipeline including extended half-life antibodies targeting α4β7, TL1A, and IL-23.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment